EL DORADO HILLS, Calif., July 6, 2005 /PRNewswire-FirstCall via COMTEX/ -- NutraCea (NTRZ) announced today the results of the second phase open label clinical trial conducted at the University of New Mexico (UNM) School of Medicine by stroke specialist, Dr. Glenn Graham, Director, Cerebrovascular Disorders Program and Principal Investigator and Dr. Wade Harris, Resident and Co-Investigator on the "Effects of Stabilized Rice Bran RiSolubles(R) on Inhibition of Platelet Aggregation and Lipid Profile."
"Of the 39 patients who completed the study, there was an average of 12.31% reduction in total cholesterol and a 10.54% reduction of LDL cholesterol, which are considered to be statistically significant findings with a p value of .00367 and .00251, respectively. The triglycerides also were reduced by 10.31% and HDL levels remained about the same. In addition, there was a non-significant trend toward increased ADP and EPI closure time suggestive of an anti-platelet effect," stated Dr. Wade Harris.
"The results of this small, but significant study are very promising and we look forward to engaging in a larger, more rigorous double blind placebo controlled study, which will compare RiSolubles(R) to one or more of the anti- thrombotic pharmaceutical drugs to further evaluate the possibility of this whole food source having therapeutic value," said Dr. Glenn Graham, Director, Cerebrovascular Disorders Program at UNM Medical School-Albuquerque and Principal Investigator of the study.
"The study findings are very encouraging and certainly warrant a more expanded study with more patients at higher dosages in a population with borderline to high cholesterol levels. We lowered the dosage from 20 grams per day in the first study to 4 grams a day in this study in a population with normal cholesterol and triglyceride levels," commented Dr. Harris.
"We are pleased by these meaningful results. These results are even more compelling when you consider that these end points were achieved with a dosage of only 4 grams of RiSolubles(R) per day in capsule form and on patients whose baseline blood fat levels were normal," said Patricia McPeak, Founder and CEO of NutraCea. "It is our intention to conduct a subsequent randomized, double blind, placebo controlled study on a larger population of patients who have high blood lipids and are at an increased risk for cardiovascular disease with UNM. Safety is always foremost at NutraCea(R) and we have demonstrated that whole foods such as RiSolubles(R) are not only safe, but have an important role in combating many of the degenerative diseases, including cardiovascular diseases."
In addition, Dr. Wade Harris was awarded "Best Scientific Presentation" for 2005 at the 29th Annual Resident-Faculty Research Day - University of New Mexico School of Medicine.
NutraCea is a leader in stabilized rice bran nutrient research and dietary supplement development. The Company has developed intellectual property to create a range of proprietary product formulations, delivery systems and whole food nutrition products. NutraCea's proprietary technology enables the creation of food and nutrition products from rice bran, normally a waste by- product of standard rice processing. In addition to its whole foods products, NutraCea develops families of health-promoting "nutraceuticals," including natural arthritic relief and cholesterol-lowering products, and all-natural "cosmeceutical" beauty aids. More information can be found in the company's filings with the SEC. and on NutraCea web site http://www.NutraCea.com.
This release contains statements that are forward looking. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission, including the company's most recent periodic report.